Current Management and the New Paradigm for ALK+ NSCLC After CROWN. (PubMed, Cancers (Basel)) - Sep 27, 2026 - "The progression-free survival (PFS) plateau at a high level > 50%, with an estimated very low annual progression rate < 2% after the third year, suggests that lorlatinib can inactivate the disease in most patients...Further strengthening of the ALK blockade with additional ALK-directed drugs could likely eliminate the small residual "leak" of late off-target resistance after the third year, while combination with emerging neoantigen-directed immunotherapies may also help control the highly aggressive and more immunogenic early-progressing tumors and facilitate cure of the disease. Universal state-of-the-art DNA/RNA NGS for newly diagnosed NSCLC is now imperative to identify and treat all ALK+ patients according to the latest therapeutic advances, which will hopefully soon also spread to earlier stages and other oncogenic drivers."
Journal • Review • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK
|
|
Petros Christopoulos; Shuo Shi
|